Breaking News Instant updates and real-time market news.

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38

Fly Intel: After Hours Movers

UP AFTER EARNINGS: America's Car-Mart (CRMT) up 9.5%... 58.com (WUBA) up 3.8%... Bilibili (BILI) up 3.7%. ALSO HIGHER: SAExploration Holdings (SAEX) up 168.4% after getting $130M in new projects... Clovis Oncology (CLVS) up 5.8% after DE Shaw reported passive 5.4% stake... ServiceNow (NOW) Up 3.6% after announced entry into S&P500 index... Okta (OKTA) up 2.2% after being upgraded to Buy at DA Davidson... Splunk (SPLK) up 1.0% after being initiated at Buy at DA Davidson. DOWN AFTER EARNINGS: Woodward (WWD) down 5.4%... Kornit Digital (KRNT) down 4.9%... Ashland Global (ASH) down 3.4%... 21Vianet (VNET) down 2.8%. ALSO LOWER: DHT Holdings (DHT) down 5.6% after equity offering... Karuna Therapeutics (KRTX) down 4.2% after equity offering... 8x8 (EGHT) down 3.9% after convertible debt offering... Intelsat (I) down 3.7% after being downgraded to In Line at Evercore... Performance Food Group (PFGC) down 3.2% after equity offering... Ellington Financial (EFC) down 2.5% after equity offering. Movers as of 18:30ET.

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

CRMT America's Car-Mart
$90.88

3.22 (3.67%)

03/28/19
BUCK
03/28/19
INITIATION
Target $103
BUCK
Buy
America's Car-Mart initiated with a Buy at Buckingham
Buckingham analyst initiated America's Car-Mart with a Buy and $103 price target.
WUBA 58.com
$50.26

-1.35 (-2.62%)

08/05/19
JEFF
08/05/19
INITIATION
Target $66.4
JEFF
Buy
58.com initiated with a Buy at Jefferies
Jefferies analyst Thomas Chong started 58.com with a Buy rating and $66.40 price target. The analyst views the company as a "secular growth story" with a proven business model in overseas markets. 58.com is a leading classified platform in China with a "huge" user base, that pursues an asset-light model, says Chong.
08/23/19
BOCM
08/23/19
DOWNGRADE
BOCM
Neutral
58.com downgraded to Neutral from Buy at BOCOM
07/17/19
07/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Micro Focus (MFGP) downgraded to Sell from Neutral at Goldman Sachs. 2. Wells Fargo (WFC) downgraded to Neutral from Outperform at Macquarie. 3. Alliance Resource Partners (ARLP) downgraded to Neutral from Buy at B. Riley FBR with analyst Lucas Pipes citing the company's "disappointing" sales volumes in Q2 for the downgrade. 4. 58.com (WUBA) downgraded to Neutral from Outperform at Credit Suisse. 5. Ralph Lauren (RL), Levi Strauss (LEVI), and PVH Corp. (PVH) downgraded to Sell from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/19
FBCO
07/16/19
DOWNGRADE
FBCO
Neutral
58.com downgraded to Neutral from Outperform at Credit Suisse
BILI Bilibili
$16.39

-0.32 (-1.92%)

08/07/19
GSCO
08/07/19
INITIATION
Target $21.5
GSCO
Buy
Bilibili initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Piyush Mubayi initiated Bilibili with a Buy rating and $21.50 price target, stating that the company has the "go-to brand" for over 100M of China's youngest internet users. Given its popularity and just 5% penetration, he sees further monetization of Bilibili's "expanding and sticky" user base and projects the company turns profitable in 2021, Mubayi tells investors.
08/27/19
SBSH
08/27/19
NO CHANGE
Target $20
SBSH
Buy
Bilibili price target lowered to $20 from $23 at Citi
Citi analyst Hillman Chan lowered his price target for Bilibili to $20 from $23 following the company's Q2 results while keeping a Buy rating on the shares. The analyst says that while accelerated monthly active user growth is the bright spot, he's still debating the wider loss and "uncertain" payback. He's "mindful" of near-term weakness for delayed licenses but remains positive on Bilibili longer term given its "rich" game pipeline.
10/09/19
NOMU
10/09/19
INITIATION
Target $18
NOMU
Buy
Bilibili initiated with a Buy rating at Nomura Instinet
Nomura Instinet analyst Jialong Shi initiated coverage of Bilibili with a Buy rating and $18 price target. The company is China's answer to YouTube with a special appeal to generation Z users, Shi tells investors in a research note. In addition to "comprehensive" content library, Bilibili has further cemented its leadership position by pioneering innovative features, such as bullet chatting, contends the analyst.
08/07/19
08/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bilibili (BILI) initiated with a Buy at Goldman Sachs. 2. Waste Connections (WCN) was initiated with an Overweight at JPMorgan, while Waste Management (WM) and Republic Services (RSG) were initiated with a Neutral. 3. Neurocrine (NBIX) initiated with an Outperform at RBC Capital. 4. Brookfield Property (BPY) initiated with an Outperformer at CIBC. 5. Dropbox (DBX) initiated with an Underperform at Bernstein. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SAEX SAExploration
$1.51

-0.05 (-3.21%)

CLVS Clovis
$7.05

0.68 (10.68%)

11/07/19
PIPR
11/07/19
NO CHANGE
PIPR
Clovis' 'solid' quarter doesn't alleviate concerns, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro reiterated a Neutral rating on Clovis Oncology, but raised his price target on shares to $4.50 from $4.00 following the company's "solid" Q3 results, which showed better-than-expected revenue from Rubraca and slowing cash burn. However, the analyst noted that Clovis' current cash is sufficient only into the second half of 2021, which is close to the time ~$100M in convertible debt comes due, and a year before the "R+N arm of ATHENA is projected to readout." Given his "concerns around ATHENA, the competitive landscape, and cash/debt," Catanzaro reiterated a Neutral rating.
10/31/19
PIPR
10/31/19
NO CHANGE
Target $4
PIPR
Neutral
Clovis price target lowered to $4 from $11 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro lowered his price target for Clovis Oncology to $4 from $11 saying data for PARP plus PD-(L)1 continues to suggest little to no benefit over PARP monotherapy for BRCA+ patients. The analyst reiterates a Neutral rating on Clovis shares.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
10/08/19
GSCO
10/08/19
NO CHANGE
Target $3
GSCO
Sell
Clovis price target lowered to $3 from $13 at Goldman Sachs
Goldman Sachs analyst Paul Choi lowered his price target for Clovis Oncology to $3 from $13 and reiterates a Sell rating on the shares. The analyst sees risk to longer term consensus estimates as he believes they embed "meaningful growth" driven from Rubraca use in prostate cancer and frontline/combo use with PD-1s. Choi reduced his peak Rubraca sales by ~25% on lower expected share in prostate and in ovarian cancers. High cash burn and its convertible debt burden will continue to be overhangs on Clovis shares, the analyst tells investors in a research note.
NOW ServiceNow
$266.56

6.65 (2.56%)

10/24/19
BMOC
10/24/19
NO CHANGE
Target $300
BMOC
Outperform
ServiceNow price target lowered to $300 from $315 at BMO Capital
BMO Capital analyst Keith Bachman lowered his price target on ServiceNow to $300, saying the company's Q3 results were "reasonable" despite the "material headwind" in FX. The analyst also cites his management "transition concern" with the move by ServiceNow's CEO to Nike along with the other recent management departures, but he keeps his Outperform rating on the stock and continues to find the company's value proposition as "compelling".
11/18/19
JEFF
11/18/19
NO CHANGE
JEFF
Buy
ServiceNow enters 2020 in better leadership position, says Jefferies
Jefferies analyst Samad Samana views the Gina Mastantuono CFO appointment by ServiceNow as a positive, saying it removes uncertainty around a key senior leadership position. The company also announced that Bill McDermott has formally assumed the role of President and CEO. Resolving the leadership situation prior to year-end removes a potential overhang and allows ServiceNow to enter 2020 in a better position, Samana tells investors in a research note. The analyst keeps a Buy rating on the shares with a $280 price target.
11/04/19
CFRA
11/04/19
UPGRADE
CFRA
Buy
ServiceNow upgraded to Buy from Hold at CFRA
CFRA upgraded ServiceNow to Buy from Hold.
11/08/19
PIPR
11/08/19
INITIATION
Target $305
PIPR
Overweight
ServiceNow assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Rob Owens assumed coverage of ServiceNow with an Overweight rating and $305 price target.
OKTA Okta
$121.21

3.76 (3.20%)

11/18/19
DADA
11/18/19
UPGRADE
DADA
Buy
Okta upgraded to Buy from Neutral at DA Davidson
DA Davidson upgraded Okta to Buy from Neutral.
11/18/19
DADA
11/18/19
UPGRADE
Target $135
DADA
Buy
Okta pullback represents 'good entry point,' says DA Davidson
As reported earlier, DA Davidson analyst Andrew Nowinski upgraded Okta to Buy from Neutral and raised his price target on the shares to $135 from $131. Nowinski said that while shares have declined 24% since the end of July, he believes the pullback represents a "good entry point" to get into one of the top Software-as-a-Service growth stocks. The analyst added that he believes the stock is capable of generating over 30% growth for the next four-plus years, combined with a free cash flow margin of 20% or higher.
11/18/19
ADAM
11/18/19
DOWNGRADE
Target $120
ADAM
Hold
Okta downgraded to Hold at Canaccord
As reported previously, Canaccord analyst Richard Davis downgraded Okta to Hold from Buy. The analyst cited its elevated valuation and said it is expensive by any valuation method and therefore fully priced. Davis lowered his price target to $120 from $145 on Okta shares.
11/18/19
ADAM
11/18/19
DOWNGRADE
Target $120
ADAM
Hold
Okta downgraded to Hold from Buy at Canaccord
Canaccord Genuity analyst Richard Davis downgraded Okta to Hold from Buy with a $120 price target.
SPLK Splunk
$122.64

3.49 (2.93%)

11/18/19
11/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. WestRock (WRK) upgraded to Buy from Neutral at BofA/Merrill with analyst George Staphos saying his takeaway from investor events attended last week suggests that the macro and sector trends for integrated containerboard companies are stable to improving and also believes that the risks in the industry are "not new." 2. Rockwell Automation (ROK) upgraded to Overweight from Equal Weight at Barclays analyst Julian Mitchell saying the stock remains out of favor with the investment community, but the recent earnings report suggests "grounds for optimism." 3. Splunk (SPLK) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying once Splunk is through its shift to a 100% recurring revenue model and annual invoicing, investors will have better visibility into a company well positioned for key secular trends in data and monitoring. 4. Owens Corning (OC) upgraded to Outperform from Market Perform at Wells with analyst Truman Patterson saying his industry contacts suggest Owens Corning announced an 8% U.S. residential insulation price hike for both loose-fill and batt and roll on Friday, effective January 13. 5. Wolverine World Wide (WWW) upgraded to Buy from Hold at Argus with analyst John Staszak saying he believes that the company will benefit from growth in footwear spending, particularly as the economy improves and consumer confidence increases. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/19
DADA
11/18/19
INITIATION
Target $150
DADA
Buy
Splunk initiated with a Buy at DA Davidson
DA Davidson analyst Andrew Nowinski initiated coverage of Splunk with a Buy rating and $150 price target. The analyst says the company's new pricing plans should improve its visibility and growth, adding that the "rapidly accelerating" momentum of its Splunk Cloud should also lead to its long-term margin expansion. Nowinski further notes that while he has some near-term concerns about the company's cash flow, he still believes that Splunk is well-positioned to increase its market share.
11/18/19
MSCO
11/18/19
UPGRADE
Target $169
MSCO
Overweight
Morgan Stanley upgrades Splunk to Overweight, says shares look undervalued
Morgan Stanley analyst Keith Weiss upgraded Splunk to Overweight from Equal Weight with a price target of $169, up from $140. The stock closed Friday up $2.21 to $119.20. Once Splunk is through its shift to a 100% recurring revenue model and annual invoicing, investors will have better visibility into a company well positioned for key secular trends in data and monitoring, Weiss tells investors in a research note. He believes Splunk can sustain 25%-plus software annual recurring revenue growth, with free cash flow margins in the mid-20s, yielding $6 in free cash flow per share. Meanwhile, Splunk shares currently trade at a 30% valuation discount relative to peers on an enterprise value to 2020 sales basis, adds Weiss. As such, he believes the stock looks undervalued at current levels.
11/18/19
DADA
11/18/19
INITIATION
DADA
Buy
Splunk initiated with a Buy at DA Davidson
DA Davidson analyst Andrew Nowinski initiated coverage of Splunk with a Buy rating.
WWD Woodward
$113.64

-1.15 (-1.00%)

06/14/19
RHCO
06/14/19
DOWNGRADE
RHCO
Hold
Woodward downgraded to Hold from Buy at SunTrust
SunTrust analyst Michael Ciarmoli downgraded Woodward Hold from Buy.
09/24/19
LEHM
09/24/19
NO CHANGE
LEHM
Barclays sees aerospace aftermarket stocks continuing to outperform in 2020
Barclays analyst David Strauss' analysis of global airline flight schedules indicates ~3% flight hour growth through the end of 2019, or 200 to 250 basis points below typical levels, due to the combination of the Boeing (BA) MAX grounding and weaker underlying traffic demand. The analyst forecasts decelerating second half of 2019 aftermarket growth as a result, given airlines dependency on older out-of-warranty aircraft. However, even with expected return of MAX in 2020, he forecasts that the aftermarket still grows 6%-8% as incremental MAX flight hours "do little to dilute contribution of continued strong growth in the older out-of-warranty fleet, which is responsible for the majority of aftermarket demand." Among his coverage, Strauss says TransDigm (TDG) is the primary beneficiary of continued aftermarket strength while Woodward (WWD) also has significant exposure. He believes the aerospace aftermarket stocks will continue to outperform in 2020 "despite elevated relative valuations."
06/14/19
06/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Transocean (RIG) downgraded to Neutral from Buy at Citi with analyst Scott Gruber saying his organic cash burn analysis implies the drillers will burn cash until "at least" 2021. 2. CommScope (COMM) downgraded to Outperform from Strong Buy at Raymond James with analyst Simon Leopold saying he is concerned that performance of the acquired ARRIS business will be worse than expected. 3. Spirit AeroSystems (SPR), Astronics (ATRO), and Barnes Group (B) were downgraded to Sell from Hold at SunTrust while Woodward (WWD) and Ducommun (DCO) were downgraded to Hold from Buy. 4. Melinta Therapeutics (MLNT) downgraded to Underweight from Neutral at JPMorgan with analyst Eric Joseph saying while a market cap valuation of $20M-25M "begs the questions of whether shares have yet reached bottom," he believes the answer is "no." 5. Ashland (ASH) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/14/19
06/14/19
DOWNGRADE

Hold
Astronics, Barnes Group, Ducommun, Woodward, Spirit Aero downgraded at SunTrust
As previously reported, SunTrust analyst Michael Ciarmoli downgraded Astronics (ATRO) to Sell, Barnes Group (B) to Sell, Ducommun (DCO) to Hold, Woodward (WWD) to Hold, and Spirit Aerosystems to Sell as part of his broader Aerospace research note highlighting the "ongoing" Boeing (BA) 737 Max uncertainty. The analyst says the risks related to the aircraft production will "ripple across the sector" over the next 12-24 months and spark outlook revisions for the supply chain in 2019-2020. Ciarmoli believes however that the downgrade will be "short term" in nature until there is better clarity around the timing of 737 Max certification, resumption of flight, and future production rates. The analyst's price target reductions on the supplier are as follows: Astronics down to $36 from $41, Barnes Group to $48 from $53, Ducommun to $48 from $54, Spirit Aerosystems to $75 from $93, and Woodward to $110 from $118.
KRNT Kornit Digital
$33.07

-1.13 (-3.30%)

06/18/19
NEED
06/18/19
NO CHANGE
Target $34
NEED
Buy
Kornit Digital price target raised to $34 from $32 at Needham
Needham analyst James Ricchiuti raised his price target on Kornit Digital to $34 and kept his Buy rating after the company's $130M equity raise last week. The analyst says the offering brings Kornit Digital's net cash position to about $250M and gives it "considerable flexibility" to pursue strategic acquisitions and to further fund its "strong" organic growth, which he expects to remain the primary catalyst for the company.
04/04/19
NEED
04/04/19
NO CHANGE
Target $30
NEED
Buy
Kornit Digital price target raised to $30 from $24 at Needham
Needham analyst James Ricchiuti raised his price target on Kornit Digital to $30 after attending the company's customer event at its headquarters where it showcased its "new disruptive Poly Pro print technology and the new mass production Atlas direct-to-garment system." The analyst says Kornit Digital's presentation has raised his optimism about his forecast of 25% revenue growth in 2019 as well as the management's scaling expectations to achieve $500M in revenue by the end of 2023. Ricchiuti claims that Kornit Digital is one of his "more compelling growth stories" and keeps his Buy rating on the shares.
05/07/19
05/07/19
NO CHANGE

Kornit Digital named a strong sell at Spruce Point
07/30/19
WBLR
07/30/19
NO CHANGE
WBLR
Outperform
Amazon's Salt Lake City permit close to final approval, says William Blair
Amazon's (AMZN) application with the Utah Department of Environmental Quality to set up an inkjet printing facility in Salt Lake City is close to final approval, William Blair analyst Brian Drab tells investors in a research note. On July 25, the DEQ sent Amazon a letter indicating intent to approve the proposed project, says the analyst. The public has about one month to comment on the approval and those comments will be considered before final approval is given, he notes. While the application and approval letter do not specify Kornit Digital (KRNT) printers, Drab is "highly confident" the printers to be installed in the facility will be supplied by Kornit. The documents describe the printing process to be employed as the application of ink immediately following the application of a fixation agent, says the analyst. Kornit is the only digital textile printer on the market using this patented process, contends Drab. The analyst now has increased confidence in his forecast for Kornit Digital for the second half of 2019 and he sees the potential for upside to current assumptions regarding revenue from Amazon. He keeps an Outperform rating on Kornit Digital.
ASH Ashland
$78.65

0.03 (0.04%)

10/14/19
MONN
10/14/19
UPGRADE
Target $88
MONN
Buy
Ashland upgraded to Buy from Neutral at Monness Crespi
Monness Crespi analyst Chris Shaw upgraded Ashland to Buy from Neutral with an $88 price target.
09/19/19
JEFF
09/19/19
NO CHANGE
Target $95
JEFF
Buy
Jefferies boosts Ashland target to $95, sees 24% total return
After $17B of acquisitions and divestitures over the past 15 years, Ashland "finally has the specialty ingredients profile it targeted," Jefferies analyst Laurence Alexander tells investors in a research note. He believes that a focus on execution should reduce the company's earnings and margin volatility, improve mix and free cash flow conversion, and support better returns on capital. Alexander believes a 12-times EBITDA valuation is achievable next year, versus the current 11.1-times, leading to a ~24% total return. He boosted his price target for Ashland shares to $95 from $93 and keeps a Buy rating on the name.
10/15/19
WELS
10/15/19
INITIATION
Target $90
WELS
Outperform
Ashland initiated with an Outperform at Wells Fargo
Wells Fargo analyst Michael Sison initiated coverage of Ashland with an Outperform rating and $90 price target.
10/15/19
WELS
10/15/19
INITIATION
Target $90
WELS
Outperform
Ashland initiated with an Outperform at Wells Fargo
Wells Fargo analyst Michael Sison initiated coverage of Ashland with an Outperform rating and $90 price target. Following recent divestitures, Ashland is a pure-play specialty chemical company with EBITDA margins on a path to move to the mid-20s, Sison tells investors in a research note. The analyst sees the company's cost saving initiatives, improved organic growth and bolt-on acquisitions driving growth for the next couple years.
VNET 21Vianet
$8.28

0.23 (2.86%)

01/14/19
MSCO
01/14/19
NO CHANGE
Target $17
MSCO
Overweight
21Vianet named research tactical idea at Morgan Stanley
Morgan Stanley analyst Yang Liu named 21Vianet as a Research Tactical Idea, stating that he believes the shares will rise in absolute terms over the next 60 days. The analyst, who believe 21Vianet is well on track to deliver its 2018 guidance and forecasts it can grow EBITDA by 15% per year in 2019-20, has a $17 price target on the stock.
DHT DHT Holdings
$7.52

-0.2 (-2.59%)

02/12/19
DNBM
02/12/19
UPGRADE
DNBM
Buy
DHT Holdings upgraded to Buy from Hold at DNB Markets
04/24/19
STFL
04/24/19
NO CHANGE
STFL
U.S. sanctions on Iran could benefit crude tankers, says Stifel
After the U.S. recently said it will re-institute sanctions on Iran on May 1 to now include the eight countries that previously had waivers, Stifel analyst Benjamin Nolan said he believes crude tankers could see a benefit. Nolan noted that much of Iran's oil is moved by their own vessels and the net effect could be increased demand for approximately 30 VLCCs from the trio of Saudi Arabia, Russia, and the UAE, who have said they are willing to fill the void left by absent Iranian barrels. Stocks in the crude tanker group include International Seaways (INSW), TEN, Ltd. (TNP), Scorpio Tankers (STNG), Euronav NV (EURN), DHT Holdings (DHT) and Ardmore Shipping (ASC).
02/12/19
02/12/19
UPGRADE

Buy
DNB Markets sees risks discounted in valuation, ups crude tanker stocks to Buy
As previously reported, DNB Markets analyst Nicolay Dyvik upgraded DHT Holdings (DHT), Euronav NV (EURN), Frontline (FRO) and Teekay Tankers (TNK) to Buy from Hold as he believes the risks he put forward in his previous downgrades are now discounted in equity values. At an EV/GAV of 0.8 times, OPEC output cuts are discounted, but IMO 2020 is not, he contended, adding that ship prices are up in the past two months, as the one-year time-charter market starts to discount IMO 2020, and with tanker stocks set to follow.
04/23/19
EVER
04/23/19
UPGRADE
EVER
Outperform
DHT Holdings upgraded to Outperform from In Line at Evercore ISI
KRTX Karuna Therapeutics
$94.70

77.44 (448.67%)

11/18/19
GSCO
11/18/19
NO CHANGE
Target $109
GSCO
Buy
Karuna Therapeutics price target raised to $109 from $35 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised his view on the odds of success of KarXT for the treatment of acute psychosis in patients with schizophrenia to 60% from 15% after Karuna Therapeutics announced results from its Phase 2 clinical trial of the drug. In his view, the strong signal of efficacy coupled with the drug's tolerability profile support use of KarXT in schizophrenia psychosis and have a positive read-through to the pipeline for Alzheimer's disease psychosis, Richter tells investors. He keeps a Buy rating on Karuna shares and raised his price target on the stock to $109 from $35.
11/18/19
SBSH
11/18/19
NO CHANGE
Target $115
SBSH
Buy
Karuna Therapeutics price target raised to $115 from $28 at Citi
Citi analyst Mohit Bansal said the phase 2 data reported by Karuna Therapeutics for KarXT appear better than expected, better than current anti-psychotics, and could be "paradigm changing." The drug's "benign" safety lead him to see the potential for use as a front line agent as well, leading the analyst to raise his peak unadjusted sales estimate in schizophrenia to $4.7B from $2.3B. Given the higher peak sales potential, and higher odds assigned for the drug's approval, Bansal raised his price target for Karuna shares to $115 from $28. The analyst, who thinks there is more upside in the stock despite today's move, keeps a Buy rating on Karuna shares, which are up $64.52, or 365%, to $82.20.
07/23/19
SBSH
07/23/19
INITIATION
Target $28
SBSH
Buy
Karuna Therapeutics initiated with a Buy at Citi
Citi analyst Mohit Bansal started Karuna Therapeutics with a Buy rating and $28 price target. If successful, the company's xanomeline would offer a new mechanism of action versus current antipsychotics, and would be the first treatment targeting negative and cognitive symptoms, Bansal tells investors in a research note. He believes the Phase 2 schizophrenia data by year-end 2019 "will further de-risk the program" and sees the opportunity in that setting reaching $2B in sales.
07/23/19
WEDB
07/23/19
INITIATION
Target $38
WEDB
Outperform
Karuna Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Karuna Therapeutics with an Outperform rating and a $38 price target. The analyst considers Karuna Therapeutics to be an opportunity to invest in a breakthrough oral treatment for symptoms and cognitive impairment associated with schizophrenia and Alzheimer's disease as well as pain. Due to millions of schizophrenia and Alzheimer's disease patients and low compliance for current "dirty" drugs available for psychosis and nothing approved for negative symptoms or cognitive impairment, Moussatos sees blockbuster sales potential for KarXT. Starting with U.S. launch in 2023, she estimates KarXT could achieve over $1B in gross peak annual sales in 2027 and more than $4B in 2030.
EGHT 8x8, Inc.
$20.78

0.13 (0.63%)

10/31/19
SRCH
10/31/19
UPGRADE
SRCH
Buy
8x8, Inc. upgraded to Buy from Hold at Summit Insights
Summit Insights analyst Jonathan Kees upgraded 8x8, Inc. to Buy from Hold following the Q3 report and raised guidance.
10/24/19
10/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Applied Materials (AMAT) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab citing competitor Lam Research's (LRCX) "strong" results and raised outlook, as he now believes he was previously too conservative. 2. Oshkosh (OSK) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying recent machinery peer reports show that guidance cuts are starting to result in multiple expansion and the company is well positioned to manage Access volatility. 3. 8x8, Inc. (EGHT) upgraded to Neutral from Sell at B. Riley FBR with Josh Nichols saying he is stepping back to the sidelines ahead of the company's fiscal Q2 results on October 30, noting that the shares have been under pressure since the Q1 report at the end of July. 4. Arvinas (ARVN) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn citing the company's presentation of the first Phase 1 data for ARV-110 for prostate cancer and ARV-471 for breast cancer at a medical summit. 5. Rogers Communications (RCI) upgraded to Outperform from Sector Perform at RBC Capital with analyst Drew McReynolds saying the sector pullback is overdone and also cites the 17% decline in Rogers stock price since the February high that has taken the enterprise value to expected forward-twelve-month EBITDA multiple down to 7.1-times vs. large-cap peer multiple of 7.5-times. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/19
RILY
10/24/19
UPGRADE
Target $18.5
RILY
Neutral
8x8, Inc. upgraded to Neutral on valuation at B. Riley FBR
B. Riley FBR analyst Josh Nichols upgraded 8x8, Inc. to Neutral from Sell with an unchanged price target of $18.50. The analyst is stepping back to the sidelines ahead of the company's fiscal Q2 results on October 30, noting that the shares have been under pressure since the Q1 report at the end of July. Investor sentiment "appears to be shifting somewhat" with an increased focus on profitability, and the stock could remain under pressure if growth and cash burn do not significantly improve, Nichols tells investors in a research note. Despite the upgrade to Neutral he believes "execution risk lingers" at current valuation levels.
10/24/19
RILY
10/24/19
UPGRADE
Target $18.5
RILY
Neutral
8x8, Inc. upgraded to Neutral from Sell at B. Riley FBR
B. Riley FBR analyst Josh Nichols upgraded 8x8, Inc. to Neutral from Sell with a $18.50 price target.
I Intelsat
$7.98

-5.42 (-40.45%)

11/18/19
EVER
11/18/19
DOWNGRADE
Target $11
EVER
In Line
Intelsat downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst James Ratcliffe downgraded Intelsat to In Line from Outperform with an $11 price target.
11/18/19
JPMS
11/18/19
NO CHANGE
Target $9
JPMS
Neutral
Intelsat price target lowered to $9 from $22 at JPMorgan
JPMorgan analyst Philip Cusick lowered his price target for Intelsat to $9 from $22 and maintains a Neutral rating on the shares after the Federal Communications Commission sided with lawmakers in backing a public auction of radio spectrum rather than a private auction. The private auction process is "officially dead," but there is still no consensus of how to get to a public auction, Cusick tells investors in a research note.
11/18/19
ARTE
11/18/19
INITIATION
Target $39
ARTE
Buy
Intelsat initiated with a Buy at Arete
Arete initiated coverage of Intelsat with a Buy rating and $39 price target.
11/18/19
EVER
11/18/19
DOWNGRADE
Target $11
EVER
In Line
Evercore downgrades Intelsat, cuts price target to $11 from $38
Evercore ISI analyst James Ratcliffe downgraded Intelsat to In Line from Outperform with a price target of $11, down from $38. The current proposals for revenue sharing and potential for litigation-related delays make the stock's risk-reward "much less attractive," Ratcliffe tells investors in a research note. Intelsat shares fell 40% today after the Federal Communications Commission head Ajit Pai backed a public auction of radio spectrum rather than a private auction. Ratcliffe believes the proposal by Senators Roger Wicker John Thune, called the 5G Spectrum Act, implies a $2 per share for Intelsat.
PFGC Performance Food Group
$46.09

-0.08 (-0.17%)

08/15/19
GUGG
08/15/19
NO CHANGE
Target $50
GUGG
Buy
Performance Food Group price target raised to $50 from $46 at Guggenheim
Guggenheim analyst John Heinbockel raised his price target on shares of Performance Food Group to $50 from $46 following Q4 results that he called "strong" and initial 2020 guidance that he views as "reasonable." The analyst, who reiterated his Buy rating on the stock and continues to view it as a Best Idea, thinks Performance is well-positioned to outperform in the current consumer environment. The company is gaining share, profitably, from competitors in both of its segments, added Heinbockel.
08/15/19
LOOP
08/15/19
NO CHANGE
Target $50
LOOP
Buy
Performance Food Group price target raised to $50 from $48 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on Performance Food Group to $50 and kept his Buy rating after its above-consensus Q4 results, with accelerated Vistar EBITDA growth. The analyst says the company's performance is driven by the growth of sales personnel as anticipated despite the headwind of flat same-store sales across independent restaurants. Wolf also notes that the stock is currently valued at the mean of its Foodservice Distribution peers on a forward earnings basis.
08/15/19
BMOC
08/15/19
NO CHANGE
Target $52
BMOC
Outperform
Performance Food Group price target raised to $52 from $48 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Performance Food Group to $52 and kept her Outperform rating after "another solid quarter" of results in Q4 highlighted the company's relative "consistency and strength in execution". The analyst anticipates a "more balanced" FY20, with a more stabilized outlook for expenses, fuel and freight along with Vistar-led EBITDA growth. Bania also notes that Performance Food Group's quarter-to-date trends appear to be "off to a solid start."
10/04/19
WELS
10/04/19
NO CHANGE
Target $53
WELS
Outperform
Wells Fargo 'not overly concerned' about Amazon threat to Performance Food Group
Wells Fargo analyst Edward Kelly said he believes food service stocks, including Performance Food Group (PFGC) in particular, are weak due to a competing analyst's note highlighting that Amazon (AMZN) had a presence at a convenience store conference, sparking concern that the e-commerce giant may be looking to enter c-store distribution. Investors may also be concerned that this news "logically reintroduces the question" of whether Amazon is interested in traditional food service distribution to restaurants, Kelly added. However, he is "not overly concerned," stating that while safe to assume Amazon is looking into these businesses, and many others, that does not guarantee a meaningful presence or success. Also, C-store distribution requires tobacco to execute broadly and it is not clear if Amazon has interest in this product, Kelly contends. The analyst, who believes c-store exposure for Sysco (SYY) and US Foods (USFD) is "tiny," added that traditional food service is a tough business for a new entrant. While Amazon's "true ambition in any industry is difficult to assess and it makes sense to remain on alert," he would be a buyer of all three food distributor stocks mentioned amid the weakness, Kelly tells investors.
EFC Ellington Financial
$18.79

0.01 (0.05%)

02/14/19
RILY
02/14/19
UPGRADE
Target $18
RILY
Buy
Ellington Financial upgraded to Buy on REIT conversion at B. Riley FBR
As previously reported, B. Riley FBR analyst Timothy Hayes upgraded Ellington Financial to Buy from Neutral and increased his price target to $18 from $16 to reflect the company's decision to convert to a REIT. He believes the change should encourage greater institutional investment, increase liquidity, and make the dividend more attractive, Hayes tells investors.
02/14/19
RILY
02/14/19
UPGRADE
RILY
Buy
Ellington Financial upgraded to Buy from Neutral at B. Riley FBR
09/27/19
NOMU
09/27/19
INITIATION
Target $20
NOMU
Buy
Ellington Financial initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Matthew Howlett initiated Ellington Financial with a Buy rating and $20 price target, citing his view that the company's recent conversion to a REIT, combined with its diversified business model, should be rewarded with a premium multiple to book value, in line with its core Mortgage REIT peers. He also sees Ellington being positioned to raise its dividend, telling investors that the company entered the second half of the year with "one of the strongest core earnings ramps in the space."

TODAY'S FREE FLY STORIES

ACB

Aurora Cannabis

$2.52

-0.095 (-3.63%)

21:25
12/10/19
12/10
21:25
12/10/19
21:25
Conference/Events
Aurora Cannabis management to meet with Cantor Fitzgerald. »

Analyst Pablo Zuanic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

SPY

SPDR S&P 500 ETF Trust

$313.58

-0.29 (-0.09%)

, SPX

S&P 500

$0.00

(0.00%)

21:00
12/10/19
12/10
21:00
12/10/19
21:00
General news
White House Navarro says 'no indication' Dec 15th tariffs will be delayed »

Comments made on Fox…

SPY

SPDR S&P 500 ETF Trust

$313.58

-0.29 (-0.09%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.07

0.025 (0.07%)

20:35
12/10/19
12/10
20:35
12/10/19
20:35
Hot Stocks
AT&T sets 2020 cost cut target of 4%, enters into accelerated $4B buyback »

John Stankey, COO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 29

    Jan

AEO

American Eagle

$15.13

-0.21 (-1.37%)

, PLCE

Children's Place

$70.67

0.68 (0.97%)

20:25
12/10/19
12/10
20:25
12/10/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AEO

American Eagle

$15.13

-0.21 (-1.37%)

PLCE

Children's Place

$70.67

0.68 (0.97%)

UNFI

United Natural Foods

$9.88

0.19 (1.96%)

VRA

Vera Bradley

$12.05

-0.09 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 18

    Dec

SAGE

Sage Therapeutics

$63.23

0.55 (0.88%)

20:15
12/10/19
12/10
20:15
12/10/19
20:15
Hot Stocks
Sage Therapeutics CSO buys 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$63.23

0.55 (0.88%)

20:14
12/10/19
12/10
20:14
12/10/19
20:14
Hot Stocks
Sage Therapeutics CEO buys 7.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XP

XP

$0.00

(0.00%)

20:11
12/10/19
12/10
20:11
12/10/19
20:11
Syndicate
XP 72.5M share IPO priced at $27.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PMT

PennyMac Mortgage

$22.75

-0.055 (-0.24%)

20:08
12/10/19
12/10
20:08
12/10/19
20:08
Syndicate
PennyMac Mortgage 8M share Spot Secondary priced at $22.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SALM

Salem Media

$1.49

0.03 (2.05%)

19:48
12/10/19
12/10
19:48
12/10/19
19:48
Hot Stocks
Salem Media cuts quarterly dividend to 2.5c from 6.5c per share »

The cash distribution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HROW

Harrow Health

$6.74

0.21 (3.22%)

19:46
12/10/19
12/10
19:46
12/10/19
19:46
Hot Stocks
Surgical Eyedrop wins return of patent from Harrow Health »

Novel Drug Solutions and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZUMZ

Zumiez

$34.02

-0.67 (-1.93%)

19:32
12/10/19
12/10
19:32
12/10/19
19:32
Hot Stocks
Zumiez director sells 5.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRC

Tejon Ranch

$16.07

0.02 (0.12%)

18:47
12/10/19
12/10
18:47
12/10/19
18:47
Hot Stocks
Ken County board of supervisors reaffirms approval of Grapevine at Tejon Ranch »

By a 5-0 vote, the Kern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$6.89

0.02 (0.29%)

, AVGO

Broadcom

$315.10

0.61 (0.19%)

18:43
12/10/19
12/10
18:43
12/10/19
18:43
Hot Stocks
Extreme Networks CEO: We've always been software driven »

In an interview on…

EXTR

Extreme Networks

$6.89

0.02 (0.29%)

AVGO

Broadcom

$315.10

0.61 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

WDFC

WD-40

$194.80

-0.94 (-0.48%)

18:36
12/10/19
12/10
18:36
12/10/19
18:36
Hot Stocks
WD-40 names Garry Ridge as new board Chairman »

WD-40 announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ASPU

Aspen Group

$7.00

0.02 (0.29%)

, OLLI

Ollie's Bargain Outlet

$60.28

(0.00%)

18:34
12/10/19
12/10
18:34
12/10/19
18:34
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Aspen…

ASPU

Aspen Group

$7.00

0.02 (0.29%)

OLLI

Ollie's Bargain Outlet

$60.28

(0.00%)

PLAY

Dave & Buster's

$40.07

-0.2 (-0.50%)

PLT

Plantronics

$22.93

-0.44 (-1.88%)

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

LDOS

Leidos

$89.63

-0.47 (-0.52%)

GME

GameStop

$6.50

0.18 (2.85%)

CORV

Correvio

$1.39

(0.00%)

AQST

Aquestive Therapeutics

$7.60

-0.14 (-1.81%)

KIDS

OrthoPediatrics

$38.40

-0.35 (-0.90%)

MDGL

Madrigal Pharmaceuticals

$118.45

1.16 (0.99%)

RCKT

Rocket Pharmaceuticals

$24.22

1.22 (5.30%)

MNTA

Momenta

$18.09

0.19 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 13

    Dec

  • 16

    Dec

  • 24

    Dec

  • 30

    Dec

NFLX

Netflix

$293.21

-9.27 (-3.06%)

, UBER

Uber

$27.89

0.18 (0.65%)

18:27
12/10/19
12/10
18:27
12/10/19
18:27
Periodicals
Peru seeks sales taxes from Netflix, Uber, Spotify, Reuters says »

Claudia Suarez of the…

NFLX

Netflix

$293.21

-9.27 (-3.06%)

UBER

Uber

$27.89

0.18 (0.65%)

SPOT

Spotify

$145.73

-0.71 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

UBS

UBS

$11.95

-0.07 (-0.58%)

18:25
12/10/19
12/10
18:25
12/10/19
18:25
Periodicals
Judge rebuffs UBS' effort to reject U.S. lawsuit, Reuters reports »

U.S. District Judge Margo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

18:25
12/10/19
12/10
18:25
12/10/19
18:25
General news
Treasury Market Summary »

Treasury Market Summary:…

AKS

AK Steel

$3.41

0.08 (2.40%)

, MT

ArcelorMittal

$17.66

-0.05 (-0.28%)

18:22
12/10/19
12/10
18:22
12/10/19
18:22
Hot Stocks
USW union expresses support for new USMCA »

United Steelworkers…

AKS

AK Steel

$3.41

0.08 (2.40%)

MT

ArcelorMittal

$17.66

-0.05 (-0.28%)

NUE

Nucor

$57.76

0.005 (0.01%)

STLD

Steel Dynamics

$34.89

-0.21 (-0.60%)

X

U.S. Steel

$13.88

-0.215 (-1.53%)

TMST

TimkenSteel

$7.23

0.12 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

, PLT

Plantronics

$22.93

-0.44 (-1.88%)

18:16
12/10/19
12/10
18:16
12/10/19
18:16
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

Choice Hotels…

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

PLT

Plantronics

$22.93

-0.44 (-1.88%)

VSI

Vitamin Shoppe

$6.50

0.005 (0.08%)

FRG

Franchise Group

$14.39

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

XP

XP

$0.00

(0.00%)

18:10
12/10/19
12/10
18:10
12/10/19
18:10
Syndicate
Breaking Syndicate news story on XP »

XP prices IPO at $27,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MSFT

Microsoft

$151.18

-0.17 (-0.11%)

17:50
12/10/19
12/10
17:50
12/10/19
17:50
Hot Stocks
Microsoft, NTT in strategic alliance for enterprise digital transformation »

NTT Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GLD

SPDR Gold Shares

$137.96

0.37 (0.27%)

17:45
12/10/19
12/10
17:45
12/10/19
17:45
Hot Stocks
SPDR Gold Shares holdings fall to 885.93MT from 886.23MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBZ

CBIZ

$27.10

0.16 (0.59%)

17:40
12/10/19
12/10
17:40
12/10/19
17:40
Hot Stocks
CBIZ chairman Gerard sells 64,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XERS

Xeris Pharmaceuticals

$8.99

0.14 (1.58%)

17:38
12/10/19
12/10
17:38
12/10/19
17:38
Hot Stocks
Xeris Pharmaceuticals reports 'positive' phase 2 data in glucagon study »

Xeris Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.